MODIFIED PTO/SB/08 (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 2, 2005

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/518,177
Int'Filing Date	6/18/2003
First Named Inventor	David BONNAFFE
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	355901-0104

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
GK	B1		WO/97/03700		Institute Pasteur De Lyon	2/6/97	English Abstract	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
GK	C1	Lortat-Jacob et al. "Interferon-Gamma Binds to Heparan Sulfate by a Cluster of Amino Acids Located in the C-terminal Part of the Molecule" *FEBS LETTERS* 280(1):152-154 (1991)	
	C2	Lortat-Jacob et al. "Non-receptor-Mediated Tissue Localization of Human Interferon-Gamma. Role of Heparan Sulfate/Heparin-Like Molecules" *Cytokine* 8(7):557-566 (1996)	
	C3	Billiau, Alfons "Interferon-Gamma: Biology and Role in Pathogenesis" *Advances in Immunol.* 62:61-130 (1996)	
GK	C4	Boutin et al. "Intrapleural Treatment with Recombinant Gamma-Interferon in Early Stage Malignant Pleural Mesothelioma" *Cancer* 74:2460-2467 (1994)	

Examiner Signature	G. Kazmierczak	Date Considered	9/11/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 2, 2005

(use as many sheets as necessary)

Sheet 2 of 5

Complete If Known	
Application Number	10/518,177
Int'Filing Date	6/18/2003
First Named Inventor	David BONNAFFE
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	355901-0104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
CK	C5	Escudier et al. "Combination of Interleukin-2 and Gamma Interferon in Metastatic renal Cell Carcinoma" *Eur. J. Cancer* 29A(5):724-728 (1993)	
	C6	Jett et al. "Phase III Trial of Recombinant Interferon Gamma in Complete Responders with Small-Cell Lung Cancer" *J. Clin. Oncol.* 12(11):2321-2326 (1994)	
	C7	Gallin, et al. "A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease" *New Engl. J. Med.* 324(8) 509-516 (1991)	
	C8	Cannon et al. "Prospective 5-Year Followup of Recombinant Interferon-Gamma in Rheumatoid Arthritis" *J. Rheumatol* 20:1867-1873 (1993)	
	C9	Czarniecki et al. "Interferon-Gamma and Resistance to Bacterial Infections" *APMIS* 101:1-17 (1993)	
	C10	Murray et al. "Interferon-Gamma and Host Antimicrobial Defense: Current and Future Clinical Applications" *Am. J. Med.* 97:459-467 (1994)	
	C11	Kakumu et al. "Treatment with Human Gamma Interferon of Chronic Hepatitis B: Comparative Study with Alpha Interferon" *J. Med. Virol.* 35:32-37 (1991)	
	C12	Freundlich et al. "Treatment of Systemic Sclerosis with Recombinant Interferon-Gamma" *Arthritis Rheum.* 35(10):1134-1142 (1992)	
	C13	Todd et al. "Interferon Gamma-1b" *Drugs* 43(1):111-122 (1992)	
	C14	Froyen et al. "Potential Therapeutic Use of Antibodies Directed Towards HuIFN-Gamma" *Biotherapy* 10:49-57 (1997)	
	C15	Ozmen et al. "Soluble Interferon-Gamma Receptor: A Therapeutically Useful Drug for Systemic Lupus Erythematosus" *J. of Interferon Res.* 14:283-284 (1994)	
	C16	Ozmen et al. "Experimental Therapy of Systemic Lupus Erythematosus: The Treatment of NZB/W Mice with Mouse Soluble Interferon-Gamma Receptor Inhibits the Onset of Glomerulonephritis" *Eur. J. Immunol* 25:6-12 (1995)	
	C17	Lortat-Jacob et al. "High-Affinity Binding of Interferon-Gamma to a basement Membrane Complex (Matrigel) *J. Clin. Invest.* 87:878-883 (1991)	
	C18	Lortat-Jacob et al. "Interferon-Gamma C-Terminal Function: New Working Hypothesis. Heparan Sulfate and Heparin, New Targets for IFN-Gamma, Protect, Relax The Cytokine and Regulate Its Activity" *Cell. Mol. Biol.* 37(3):253-260 (1991)	
CK	C19	Lortat-Jacob et al. "Heparin Decreases the Blood Clearance of Interferon-Gamma and Increases its Activity by Limiting the Processing of its Carboxyl-terminal Sequence" *J. of Biol. Chem.* 271(27):16139-16143 (1996)	

Examiner Signature	G. Kazim	Date Considered	9/11/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 2, 2005

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known	
Application Number	10/518,177
Int'Filing Date	6/18/2003
First Named Inventor	David BONNAFFE
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	355901-0104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
CdC	C20	Halme et al. "Inhaled Recombinant Interferon Gamma in Patients with Lung Cancer: Pharmacokinetics and Effects on Chemiluminescence Responses of Alveolar Macrophages and Peripheral Blood Neutrophils and Monocytes" *Int. J. Radiat. Oncol. Biol. Phys.* 31(1):93-101 (1995)	
	C21	Lack et al. "Nebulized INFN-Gamma Inhibits the Development of Secondary Allergic Responses in Mice" *J. Immunol.* 157:1432-1439 (1996)	
	C22	Short et al. "Percutaneous Absorption of Biologically-Active Interferon-gamma in a Human Skin Graft-Nude Mouse Model" *Pharm. Res.* 13(7):1020-1027 (1996)	
	C23	Lortat-Jacob et al. "Molecular Organization of the Interferon Gamma-Binding Domain in Heparan Sulphate" *Biochem. J.* 310:497-505 (1995)	
	C24	Lee, et al. "Synthesis of 3-(2-Aminoethylthio)Propyl Glycosides" *Carbohydrate Res.* 37:193-201 (1974)	
	C25	Schmidt et al. "New Methods for the Synthesis of Glycosides and Oligosaccharides – Are There Alternatives to the Koenigs-Knorr Method?" *Agnew Chem. Int. Ed. Engl.* 25:212-235 (1986)	
	C26	Klotz et al. "Anomeric *O*-Alkylation of *O*-Unprotected Hexoses and Pentoses – Convenient Synthesis of Decyl, Benzyl, and Allyl Glycosides" *Liebigs. Ann. Chem.* 683-690 (1993)	
	C27	Klotz et al. "Anomeric *O*-Alkylation of *O*-Acetyl-Protected Sugars" *J. Carbohydrate Chemistry* 13(8):1093-1101 (1994)	
	C28	Terjung et al. "New 2/2-Type Surfactants Via Anomeric *O*-Alkylation of Mannofuranose" *Carbohydr. Res.* 297:229-242 (1997)	
	C29	Lubineau et al. "Syntheses of α-Linked Derivatives of *N*-Acetyl Glucosamine and Gal-β(1-3)GalNAc (T Antigen) Directly with the Natural *N*-Acetyl Protecting Group" *J.Chem. Soc. Chem. Commun.* 1918-1919 (1989)	
	C30	Lubineau et al. "Stereoselectivity Control in Anomeric *O*-Alkylation. Application to the Synthesis of C_2 Symmetric Glycoconjugates" *Tetrahedron Letters* 38(23):4087-4090 (1997)	
	C31	Sakairi et al. "Synthesis of a Conformationally Constrained Heparin-Like Pentasaccharide" *Chem. Eur. J.* 2(8):1007-1013 (1996)	
	C32	Petitou et al. "A Synthetic Heparin/Heparan Sulfate-Like Decasaccharide Releases Lipase Activity *In Vivo*. Chemical Synthesis and Biological Activity" *Bioorg. Med. Chem. Lett.* 7(15):2067-2070 (1997)	
	C33	Petitou et al. "First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin" *Agnew. Chem. Int. Ed.* 37(21):3009-3014	
BK	C34	Lei et al. "Synthesis of a 3-Deoxy-L-Iduronic Acid Congtaining Heparin Pentasaccharide to Probe the Conformation of the Antithrombin III Binding Sequence" *Boorgan. & Med. Chem.* 6:1337-1346 (1998)	

Examiner Signature	G. Kaznik	Date Considered	9/11/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 2, 2005

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known	
Application Number	10/518,177
Int'l Filing Date	6/18/2003
First Named Inventor	David BONNAFFE
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	355901-0104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
GK	C35	Basten et al. "In Vitro Evaluation of Synthetic Heparin-Like Conjugates Comprising different Thrombin Binding Domains" *Bioorg. Med. Chem. Lett.* 8:1201-1206 (1998)	
	C36	Duchaussoy et al. "Identification of a Hexasaccharide Sequence Able to Inhibit Thrombin and Suitable for 'Polymerisation'" *Carbo. Res.* 317:63-84 (1999)	
	C37	Duchaussoy et al. "Assessment Through Chemical Synthesis of the Size of the Heparin Sequence Involved in Thrombin Inhibition" *Carbo. Res.* 317:85-99 (1999)	
	C38	Koshida et al. "Synthesis of Heparin Partial Structures and their Binding Activities to Plateletes" *Bioor. Med. Chem. Lett.* 9:3127-3132 (1999)	
	C39	Kovensky et al. "A Synthetic Heparin Sulfate Pentasaccharide, Exclusively Containing L-Iduronic Acid, Displays Higher Affinity for FGF-2 than its D-Glucuronic Acid-Containing Isomers" *Bioor. & Med. Chem.* 7:1567-1580 (1999)	
	C40	La Ferla et al. "Synthesis of Disaccharide Sub-Units of a New Series of Heparin Related Oligosaccharides" *Tetrahedron* 55:9867-9880 (1999)	
	C41	Lubineau et al. "New Accesses to L-Iduronyl Synthons" *Tetahedron Lett.* 41:307-311 (2000)	
	C42	Macher et al. "Synthesis of L-Idofuranurono-6,3-Lactone and Its Derivatives *via* Hexodialdodifuranoses" *Carbo. Res.* 80:45-51 (1980)	
	C43	Jacquinet et al. "Synthesis of Heparin Fragments. A Chemical Synthesis of the Trisaccharide *o*-(2-Deoxy-2-Sulfamido-3,6-Di-*O*-Sulfo-α-D-Glucopyranosyl), etc." *Carbo. Res.* 130:221-241 (1984)	
	C44	Baggett et al. "Re-examination of the acid hydrolysis of 5,6-Anhydro-1,2-*O*-Isopropylidene-β-L-Idofuranose" *Carbo. Res.* 127:149-153 (1984)	
	C45	Medakovic et al. "An Efficient Synthesis of Methyl 1,2,3,4-tetra-*O*-acetyl-β-L-Idopyranuronate" *Carbo. Res.* 253:299-300 (1994)	
	C46	Dromowicz et al. "A Convenient Synthesis of D-Idose" *Carbo. Res.* 308:169-171 (1998)	
	C47	Hinou et al. "Novel Synthesis of L-Iduronic Acid Using Trehalose as the Disaccharidic Starting Material" *Tetrahedron Lett.* 40:1501-1504 (1999)	
	C48	Adinolfi et al. "Intramolecular Tishchenko Reactions of Protected Hexos-5-Uloses: a Novel and Efficient Synthesis of L-Idose and L-Altrose" *Synlett* 3:336-338 (1999)	
GK	C49	Ojeda et al. "A New Route to L-Iduronate Building-blocks for the Synthesis of Heparin-like Oligosaccharides" *Synlett* 8:1316-1318 (1999)	

Examiner Signature	G. Kaplan	Date Considered	9/11/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 2, 2005

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known	
Application Number	10/518,177
Int'Filing Date	6/18/2003
First Named Inventor	David BONNAFFE
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	355901-0104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
GK	C50	Takahashi et al. "A Novel and Practical Synthesis of L-Hexoses from D-Glycono-1,5-Lactones" *J. Am. Chem. Soc.* 122:2995-3000 (2000)	
	C51	Horton et al. "Ethynylation of 1,2-O-Isopropylidene-α-D-*xylo*-Pentadialdose derivatives. A Synthetic Route to Uronic Acids" *Carbo. Res.* 14:159-171 (1970)	
	C52	Danishefsky et al. "On the Communication of Chirality from Furanose and Pyranose Rings to Monosaccharide Side Chains: Anomalous Results in the Glucose Series" *Tetrahedron* 42(11):2809-2819 (1986)	
	C53	Vasella et al. "194. Convenient Synthesis of 2-Azido-2-deoxy-aldoses by Diazo Transfer" *Helvetica Chemica Acta.* 74:2073-2077 (1991)	
	C54	Alper et al. "Metal Catalyzed Diazo transfer for the Synthesis of Azides from Amines" *Tetrahedron Lett.* 37(34):6029-6032 (1996)	
	C55	Tabeur et al. "Oligosaccharides Corresponding to the Regular Sequence of Heparin: Chemical Synthesis and Interaction with FGF-1" *Bioorg. & Medic. Chem.* 7:2003-2012 (1999)	
	C56	Oltvoort et al. "Use of the Cationic Iridium Complex 1,5-Cyclooctadiene-bis[methyldiphenylphosphine]-iridium Hexafluorophosphate in Carbohydrate Chemistry: Smooth Isomerication of Allyl Ethers to 1-Propenyl Esters" *Synethsis* 305-308 (1981)	
	C57	Dianzani F. "Interferon Treatments: How to Use an Endogenous System as a Therapeutic Agent" *J. of Interferon Res.* Special Issue May 1992, pp 109-118	
GK	C58	Horton et al. "Preparation of Derivatives of L-Idose and L-Iduronic Acid from 1,2-O-Isopropylidene-α-D-Glucofuranose by Way of Acetylnic Intermediates" *Carbo. Res.* 58:89-108 (1977)	

Examiner Signature	G. Kaźmierczak	Date Considered	9/11/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.